Tuesday , November 5 2024
Home / Mike Norman Economics / Successful Not-for-Profit Oxford COVID Vaccine Threatens Big Pharma Profit Logic

Successful Not-for-Profit Oxford COVID Vaccine Threatens Big Pharma Profit Logic

Summary:
“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean BakerThe world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Jodi Beggs writes Economists Do It With Models 1970-01-01 00:00:00

Mike Norman writes 24 per cent annual interest on time deposits: St Petersburg Travel Notes, installment three — Gilbert Doctorow

Lars Pålsson Syll writes Daniel Waldenströms rappakalja om ojämlikheten

Merijn T. Knibbe writes ´Fryslan boppe´. An in-depth inspirational analysis of work rewarded with the 2024 Riksbank prize in economic sciences.

“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean Baker


The world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the hospital as a result of being immunized. The U.K. government has already ordered 100 million doses.


Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *